换一批
换一批Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
作者：
主题词
科学院和研究所(Academies and Institutes);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗生素预防(Antibiotic Prophylaxis);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);无病生存(Disease-Free Survival);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);女(雌)性(Female);随访研究(Follow-Up Studies);基因缺失(Gene Deletion);基因, p53(Genes, p53);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);Logistic模型(Logistic Models);男(雄)性(Male);甲泼尼龙(Methylprednisolone);中年人(Middle Aged);比例危险度模型(Proportional Hazards Models);缓解诱导(Remission Induction);危险性评估(Risk Assessment);存活率(Survival Rate);治疗结果(Treatment Outcome)
DOI
10.1200/JCO.2011.35.9695
PMID
22493413
发布时间
2020-12-15
- 浏览34
Journal of clinical oncology
1647-55页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
